Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Full-Breadth Analysis of CD8 + T-Cell Responses in Acute Hepatitis C Virus Infection and Early Therapy
2005
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis
2016 StandoutNobel
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNatureNobel
Replication of a hepatitis C virus replicon clone in mouse cells.
2006
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Inflammation and metabolic disorders
2006 StandoutNature
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
Interfering with hepatitis C virus RNA replication
2004 StandoutNobel
Hepatitis C Virus Infection
2001 Standout
Impact of obesity on treatment of chronic hepatitis C†
2006
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
2002
Treatment triumphs
2014 StandoutNatureNobel
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Hepatitis B: Reflections on the current approach to antiviral therapy
2008
The influence of T cell cross-reactivity on HCV-peptide specific human T cell response
2006
Hepatitis B Virus Infection
2008
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
2008
Effect of pegylation on pharmaceuticals
2003 Standout
Interaction between hepatitis C virus proteins and host cell factors
2002 StandoutNobel
Natural history of chronic hepatitis C
2002
Preferential loss of IL‐2–secreting CD4+ T helper cells in chronic HCV infection†
2005
Vitamin D Deficiency
2007 Standout
Hepatitis B virus infection
2009 Standout
Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
2011
Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies
2001
Silencing of USP18 Potentiates the Antiviral Activity of Interferon Against Hepatitis C Virus Infection
2006 StandoutNobel
T‐cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C†
2005
Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003
2004
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
2005
Global epidemiology of hepatitis C virus infection
2005 Standout
Natural and iatrogenic variation in hepatitis B virus
1999
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
2006
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Treating viral hepatitis C: efficacy, side effects, and complications
2006
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response
1996
Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs
2002
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
2004 Standout
Detection of Functionally Altered Hepatitis C Virus–Specific Cd4+ T Cells in Acute and Chronic Hepatitis C
2003
Cytokine, Sickness Behavior, and Depression
2009
Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B
2003
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
2009 StandoutNatureNobel
Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression
2010
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Viral hepatitis C
2003
Treatment of Chronic HCV Infection in Special Populations
2006
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
2000
Occult hepatitis B virus infection
2006
Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial
2004
Revealing the world of RNA interference
2004 StandoutNatureNobel
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase
2005 StandoutNatureNobel
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment[1], [2] and [3] 1 2 3☆
2004
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004
Hepatitis C therapeutics: current status and emerging strategies
2002
A genetically humanized mouse model for hepatitis C virus infection
2011 StandoutNatureNobel
Pegylation
2001
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
2001 Standout
Isolation of novel virus-like sequences associated with human hepatitis
1995 Standout
Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs
2003
Protein therapeutics: a summary and pharmacological classification
2007 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
New therapeutic strategies for hepatitis C
2002 StandoutNobel
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end
2013
Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
2004
Rewiring cellular networks by members of the Flaviviridae family
2018
A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
2001
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication
2003 StandoutNobel
Memory T-Cell-Mediated Immune Responses Specific to an Alternative Core Protein in Hepatitis C Virus Infection
2004
Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells
2004
Molecular and serologic analysis in the transmission of the GB hepatitis agents
1995
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors.
1996 StandoutNobel
Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-α/β on antigen cross-presentation
2006 StandoutNobel
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Development of prophylactic and therapeutic vaccines against hepatitis C virus
2005
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
2005 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
A bacterial Argonaute with noncanonical guide RNA specificity
2016 StandoutNobel
An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication
2004 StandoutNobel
Marked decrease of neuropeptide Y Y2 receptor binding sites in the hippocampus in murine prion disease
1997 StandoutNobel
Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon α-2a for the Treatment of Hepatitis C
2001
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase
2013 StandoutNobel
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
2004 Standout
Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients
2003 StandoutNobel
Future Therapies for Hepatitis C
2006
Protein-Protein Interactions between Hepatitis C Virus Nonstructural Proteins
2003
Negative Regulation of NK Cell Activities by Inhibitory Receptor CD94/NKG2A Leads to Altered NK Cell-Induced Modulation of Dendritic Cell Functions in Chronic Hepatitis C Virus Infection
2004
Cell-Mediated Immunity and the Outcome of Hepatitis C Virus Infection
2004
Bone metabolism and disease in chronic kidney disease
2003
Induction of Primary Human T Cell Responses against Hepatitis C Virus-Derived Antigens NS3 or Core by Autologous Dendritic Cells Expressing Hepatitis C Virus Antigens: Potential for Vaccine and Immunotherapy
2006
Natural history of chronic hepatitis C
2002
Works of J. Rasenack being referenced
Frequency of hepatitis C in acute post‐transfusion hepatitis after open‐heart Surgery: A prospective study in 1,476 patients
1993
Sequence analysis of hepatitis B virus DNA in immunologically negative infection
1993
Antibodies and viremia in acute post‐transfusion hepatitis C: A prospective study
1994
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
2005
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
2007
Acute hepatitis C without and with schistosomiasis: Correlation with hepatitis C–Specific CD4+ T-cell and cytokine response
2001
Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin
2006
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
2000
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics
2004
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon α for chronic hepatitis C
2003
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment
2000
Clinical, virological and histopathological features: long‐term follow‐up in patients with chronic hepatitis C co‐infected with S. mansoni
2000
Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C
2002
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
2015
1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY
2012
Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients
1995
Cellular Immune Responses in Seronegative Sexual Contacts of Acute Hepatitis C Patients
2004
Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2A (PEGASYS™) for chronic hepatitis C. A multinational, randomized study
2000
328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1
2003
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
2005